【摘要】 目的:比较艾司西酞普兰与舍曲林治疗阿尔茨海默病(AD)伴发抑郁症状的临床疗效和安全性。方法:60例伴发抑郁症状的诊断为AD的患者,随机分成两组,分别用艾司西酞普兰和舍曲林治疗6周。采用蒙哥马利-阿斯伯格抑郁评价量表(MADRS),副反应量表(TESS)和简明智力状态检查(MMSE)于治疗前和治疗1、2、4、6周末分别评定疗效和不良反应。结果:艾司西酞普兰组有效率为70%,舍曲林组为63%,两组比较,无显著性差异(P>0.05),但艾司西酞普兰组起效快。两组药物有关的不良反应出现频率比较,无显著性差异(P>0.05)。两者均不会加重AD患者的认知功能。结论:艾司西酞普兰和舍曲林治疗阿尔茨海默病伴抑郁症状疗效确切,服药依从性好,两组的不良反应均较轻微,两者不会加重AD患者的认知功能。艾司西酞普兰起效快,有望作为阿尔茨海默病伴发抑郁症状的一线用药。更多还原

【Abstract】 Objective: To compare the efficacy and security of Escitalopram and Sertraline in the treatment of depression induced by Alzheimer disease (AD). Methods: 60 patients with depression induced by AD were randomly divided into the treatment groups of Escitalopram and Sertraline for 6 weeks. Clinical progress was examined with MADRS, TESS and MMSE at the pre-treatment and the end of 1,2,4,6 week after treatment. Results: The response rate was 70% for Escitalopram group and 63% for Sertraline group respectively, without statistically significant difference between two groups (P>0.05), but Escitalopram had a quick effect. The comparison of the adverse events frequency rates of two groups had no differencial meaning (P>0.05). The two drugs did not aggravate the cognitive function of AD patients. Conclusion: Escitalopram and Sertraline have similar therapeutic efficacy and good compliance in the treatment of depression associated with Alzheimer disease, all the side effects were mild, the two drugs did not aggravate the cognitive function of AD patients. Escitalopram has a quick effect, could be the first-line of preferred antidepressants in the treatment of depression associated with Alzheimer disease.更多还原